Navigation Links
Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod)

Investigational Drug Being Pursued for the Treatment of Ischemic Stroke

GLASGOW, Scotland, May 31, 2007 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI) announced today the presentation of new analysis of data from prior clinical trials of ancrod and updates on the clinical development of their investigational drug, Viprinex (ancrod), for the treatment of acute ischemic stroke at the 16th annual European Stroke Congress in Glasgow, Scotland in the United Kingdom. Viprinex is a defibrinogenating agent derived from the venom of the Malayan pit viper.

"The ancrod data presented this week in Glasgow draws positive conclusions that support a new dosing regimen for ancrod and revised inclusion/exclusion criteria for the current clinical trials," said David Sherman, MD, University of Texas Health Science Center at San Antonio. "The reanalysis enables us to see that ancrod may be safe and effective when administered to patients within six hours of stroke onset. With so few treatments currently available to stroke patients, we look forward to the results of the international phase 3 trials. We hope the phase 3 results provide evidence of definitive safety and efficacy of ancrod in ischemic stroke in the six-hour time window."

    Viprinex(TM)-related sessions at the 2007 European Stroke Congress are:

    -- Poster Session II P 29: Ancrod in a Six Hour Time Window? Evidence For

       and Against Efficacy  by D.G.Sherman University of Texas Health Science

       Center at San Antonio, USA Thursday,  31 May 2007 13:00 to 14:00 GMT

    -- Ongoing Trials Abstract #19: Ancrod Stroke Program (ASP): Two Phase 3

       International, Multi-Center, Randomized, Double-Blind,

       Placebo-Controlled Trials of Ancrod in Acute Ischaemic Stroke by David

       E. Levy, MD (Neurobiological Technologies)

NTI is moving forward with two international, randomized, double-blind, placeb
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Inspire Announces Presentations at Two European Scientific Conferences
6. IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting
7. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
8. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
9. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
10. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
11. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting
Post Your Comments:
(Date:8/31/2015)... Aug. 31, 2015  On August 5, 2015, the ... Oregon denied motions to dismiss securities class ... ) and certain of its directors. The class actions ... and dump" scheme to artificially inflate Galena,s stock price, ... stock price was inflated, sold massive amounts of their ...
(Date:8/31/2015)... , Aug. 31, 2015  Regulatory affairs ... government, where regulations are often strict and legislation ... driving a demand for professionals who have a ... regulations across a product lifecycle and demonstrate its ... University of California, Irvine Extension , in ...
(Date:8/31/2015)... SAN DIEGO , Aug. 31, 2015 ... announced today development of a novel means of ... nucleic acid, RGBP-248, to liver tumors utilizing a ... in development overcomes previous hurdles with gene silencing ... to be delivered throughout the whole body.  By ...
Breaking Medicine Technology:Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX ... that Acetadote® ( acetylcysteine ) Injection, an injectable product ... available in the Australian market. Phebra Pty Ltd., an ... U.S.-based Cumberland Pharmaceuticals to market and distribute the product ...
... Biotechnology Corporation (Nasdaq: GNBT ) ( www.generex.com ) ... reverse stock split proposal put forward at the Annual Meeting ... DO NOT COUNT as votes cast in respect of ... Special Meeting of stockholders scheduled for 10 a.m. EDT on ...
Cached Medicine Technology:Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 2Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 3Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 4Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 5Generex Provides Clarification for Special Meeting Voting 2Generex Provides Clarification for Special Meeting Voting 3
(Date:8/31/2015)... , ... August 31, 2015 , ... In an ... Press, the expert guest author addressed the topic of treating back pain caused by ... while steroids were shown to slightly improve physical function in patients suffering from a ...
(Date:8/31/2015)... ... August 31, 2015 , ... Wound Care Advantage, a leader ... Introduction to Hyperbaric Medicine Course. The next UHMS approved 40-hour Introduction to Hyperbaric ... in Long Beach, CA. The meeting is open for registration from physicians, clinicians ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... management program that is unique to the Lake Orion area. This program is ... County. , WEmovestrong’s weight management program will incorporate group fitness and nutritional ...
(Date:8/31/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... August ... ... Movestrong, has launched pre and postnatal fitness classes. , Starting September ... The classes are called "The Mom Bod" and "Healthy Body, Healthy Baby." , ...
(Date:8/31/2015)... Los Angeles, CA (PRWEB) , ... August 31, 2015 , ... ... to start from and those who are interested in learning more about the procedure ... Dr. Parsa Mohebi. , Internationally recognized hair transplant surgeon Parsa Mohebi will be ...
Breaking Medicine News(10 mins):Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2
... add anti-smoking public service announcements to all DVD releases ... Attorney General // Joseph Curran initiated the petition after ... smoking in movies are more likely to begin smoking.' ... sign their names on a letter he sent to ...
... claim of having produced and purified stem cells from human ... in the British medical fraternity. ,The Guardian reported Friday ... impose tighter curbs on clinics in India that make extravagant ... doctor whose claims have evoked some concern here is Geeta ...
... licensed therapists do is no laughing matter. These ... 49 laughing therapists recently passed their // examinations and ... their immune system, and in general to help prevent ... the organizing Nihon Medical School., ,A doctor herself, ...
... high-risk medication by the FDA, doctors have been found to ... patients found to receive // such drugs was nearly ... and Harvard Pilgrim Health Care. ,The response of the ... variable, with noncompliance rates soaring from 0.3 % to 49.6%. ...
... a King County Superior Court jury in Seattle, Dr. Charles ... two counts // of rape and two counts of indecent ... treatment. ,Momah could face 16 years in prison if ... ,Momah pleaded not guilty last year to two counts ...
... performed a rare mother-to-son nerve transplant on Thursday, hoping to ... surgery on Nick Anderson of Atco, N.J., went as planned, ... in a few months, said Eric Vohr, a spokesman for ... success in three months, in about a year they should ...
Cached Medicine News:Health News:British Scientists Doubt Delhi Doctor’s Stem Cell Claim 2Health News:Are You Ill? Have A Hard Laugh! 2Health News:Doctors Do Not Excise Sufficient Caution While Prescribing High-Risk Drugs 2Health News:Doctors Finish Mother-To-Son Nerve Surgery 2
... Erythropoietin (EPO) is the primary known ... The predicted molecular weight of human EPO ... circulating form of EPO has an estimated ... itself appears to have a unique structure, ...
... the parafollicular C-cells of the thyroid gland ... major action of calcitonin is to lower ... resulting in decreased mobilization of calcium from ... in conditions associated with high levels of ...
... (hCG) is a two chain (alpha- and ... tissue of the placenta and is normally ... Produced by the trophoblastic epithelium of the ... luteum in the early stages of pregnancy. ...
... Compensating for movement is ... in wheelchairs. Thats why ... exclusive technology to do ... with state-of-the-art technology, these ...
Medicine Products: